Anti-EGFR-iRGD Recombinant Protein Conjugated Silk Fibroin Nanoparticles for Enhanced Tumor Targeting and Antitumor Efficiency

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Jun 18

PMID 27313461

Citations 21

Authors

Xinyu Bian

Puyuan Wu

Huizi Sha

Hanqing Qian

Qing Wang

Lei Cheng

Yang Yang

Mi Yang

Baorui Liu

Affiliations

Soon will be listed here.

Abstract

In this study, we report a novel kind of targeting with paclitaxel (PTX)-loaded silk fibroin nanoparticles conjugated with iRGD-EGFR nanobody recombinant protein (anti-EGFR-iRGD). The new nanoparticles (called A-PTX-SF-NPs) were prepared using the carbodiimide-mediated coupling procedure and their characteristics were evaluated. The cellular cytotoxicity and cellular uptake of A-PTX-SF-NPs were also investigated. The results in vivo suggested that NPs conjugated with the recombinant protein exhibited more targeting and anti-neoplastic property in cells with high EGFR expression. In the in vivo antitumor efficacy assay, the A-PTX-SF-NPs group showed slower tumor growth and smaller tumor volumes than PTX-SF-NPs in a HeLa xenograft mouse model. A real-time near-infrared fluorescence imaging study showed that A-PTX-SF-NPs could target the tumor more effectively. These results suggest that the anticancer activity and tumor targeting of A-PTX-SF-NPs were superior to those of PTX-SF-NPs and may have the potential to be used for targeted delivery for tumor therapies.

Citing Articles

Advances in cell membrane-based biomimetic nanodelivery systems for natural products.

Zhang Y, Zhang Q, Li C, Zhou Z, Lei H, Liu M Drug Deliv. 2024; 31(1):2361169.

PMID: 38828914 PMC: 11149581. DOI: 10.1080/10717544.2024.2361169.

cRGD-Functionalized Silk Fibroin Nanoparticles: A Strategy for Cancer Treatment with a Potent Unselective Naphthalene Diimide Derivative.

Pirota V, Bisbano G, Serra M, Torre M, Doria F, Bari E Cancers (Basel). 2023; 15(6).

PMID: 36980611 PMC: 10046852. DOI: 10.3390/cancers15061725.

A Comprehensive Review on Silk Fibroin as a Persuasive Biomaterial for Bone Tissue Engineering.

Li M, You J, Qin Q, Liu M, Yang Y, Jia K Int J Mol Sci. 2023; 24(3).

PMID: 36768980 PMC: 9917095. DOI: 10.3390/ijms24032660.

Silk Bioconjugates: From Chemistry and Concept to Application.

Matthew S, Seib F ACS Biomater Sci Eng. 2023; 10(1):12-28.

PMID: 36706352 PMC: 10777352. DOI: 10.1021/acsbiomaterials.2c01116.

Trojan-horse silk fibroin nanocarriers loaded with a re-call antigen to redirect immunity against cancer.

Bari E, Ferrera F, Altosole T, Perteghella S, Mauri P, Rossi R J Immunother Cancer. 2023; 11(1).

PMID: 36697251 PMC: 9950976. DOI: 10.1136/jitc-2022-005916.

References

Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

Creixell M, Bohorquez A, Torres-Lugo M, Rinaldi C . EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise. ACS Nano. 2011; 5(9):7124-9. DOI: 10.1021/nn201822b. View

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Greenwald D . Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010; 328(5981):1031-5. PMC: 2881692. DOI: 10.1126/science.1183057. View

Wang A, Langer R, Farokhzad O . Nanoparticle delivery of cancer drugs. Annu Rev Med. 2011; 63:185-98. DOI: 10.1146/annurev-med-040210-162544. View

Sha H, Zou Z, Xin K, Bian X, Cai X, Lu W . Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. J Control Release. 2015; 200:188-200. PMC: 5008032. DOI: 10.1016/j.jconrel.2014.12.039. View

Sinha R, Kim G, Nie S, Shin D . Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006; 5(8):1909-17. DOI: 10.1158/1535-7163.MCT-06-0141. View

Liu P, Li Z, Zhu M, Sun Y, Li Y, Wang H . Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J Mater Sci Mater Med. 2009; 21(2):551-6. DOI: 10.1007/s10856-009-3925-8. View

Liechty W, Peppas N . Expert opinion: Responsive polymer nanoparticles in cancer therapy. Eur J Pharm Biopharm. 2011; 80(2):241-6. PMC: 3269567. DOI: 10.1016/j.ejpb.2011.08.004. View

10.

Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F . Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer. 2003; 108(3):464-72. DOI: 10.1002/ijc.11539. View

11.

Yao H, Ju R, Wang X, Zhang Y, Li R, Yu Y . The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials. 2011; 32(12):3285-302. DOI: 10.1016/j.biomaterials.2011.01.038. View

12.

Park D, Kim J, Lew Y, Kim D, Namkoong S . Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol. 2004; 92(1):59-63. DOI: 10.1016/j.ygyno.2003.09.015. View

13.

Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Girard O . Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009; 16(6):510-20. PMC: 2791543. DOI: 10.1016/j.ccr.2009.10.013. View

14.

Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher P, Mandal M . ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. J Cell Physiol. 2010; 226(2):375-84. DOI: 10.1002/jcp.22343. View

15.

Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez J . Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol. 2008; 73(4):1290-300. DOI: 10.1124/mol.107.042382. View

16.

Wang X, Kaplan D . Functionalization of silk fibroin with NeutrAvidin and biotin. Macromol Biosci. 2010; 11(1):100-10. DOI: 10.1002/mabi.201000173. View

17.

Wu P, Liu Q, Li R, Wang J, Zhen X, Yue G . Facile preparation of paclitaxel loaded silk fibroin nanoparticles for enhanced antitumor efficacy by locoregional drug delivery. ACS Appl Mater Interfaces. 2013; 5(23):12638-45. DOI: 10.1021/am403992b. View

18.

Chari . Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev. 2000; 31(1-2):89-104. DOI: 10.1016/s0169-409x(97)00095-1. View

19.

Popovtzer R, Agrawal A, Kotov N, Popovtzer A, Balter J, Carey T . Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett. 2009; 8(12):4593-6. PMC: 2772154. DOI: 10.1021/nl8029114. View

20.

Nichols J, Bae Y . EPR: Evidence and fallacy. J Control Release. 2014; 190:451-64. DOI: 10.1016/j.jconrel.2014.03.057. View